Temre Johnson - Alpine Immune Head Communications
| ALPNDelisted Stock | USD 12.37 0.23 1.83% |
Insider
Temre Johnson is Head Communications of Alpine Immune Sciences
| Phone | 206 788 4545 |
| Web | https://www.alpineimmunesciences.com |
Alpine Immune Management Efficiency
The company has return on total asset (ROA) of (0.101) % which means that it has lost $0.101 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1467) %, meaning that it created substantial loss on money invested by shareholders. Alpine Immune's management efficiency ratios could be used to measure how well Alpine Immune manages its routine affairs as well as how well it operates its assets and liabilities.Alpine Immune Sciences currently holds 9.91 M in liabilities with Debt to Equity (D/E) ratio of 0.17, which may suggest the company is not taking enough advantage from borrowing. Alpine Immune Sciences has a current ratio of 2.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Alpine Immune's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Liean MS | Acumen Pharmaceuticals | N/A | |
| Misbah Tahir | IGM Biosciences | 49 | |
| Guizhong Liu | Adagene | 53 | |
| Oliver Daltrop | MoonLake Immunotherapeutics | N/A | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| Eric Devroe | Acrivon Therapeutics, Common | 45 | |
| Bruce Keyt | IGM Biosciences | 71 | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| Joan Wood | Stoke Therapeutics | N/A | |
| Nicholas Keen | Bicycle Therapeutics | 56 | |
| Suzette Tauber | IGM Biosciences | 60 | |
| Bruce Conklin | Tenaya Therapeutics | N/A | |
| Gillian Langford | Bicycle Therapeutics | N/A | |
| Leone MBA | Tenaya Therapeutics | 62 | |
| Deepak MD | Tenaya Therapeutics | 58 | |
| Fangyong Du | Adagene | 54 | |
| Peter MD | Acrivon Therapeutics, Common | 61 | |
| Tom Holmes | Amylyx Pharmaceuticals | N/A | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.15 | |||
| Return On Asset | -0.1 |
Alpine Immune Sciences Leadership Team
Elected by the shareholders, the Alpine Immune's board of directors comprises two types of representatives: Alpine Immune inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alpine. The board's role is to monitor Alpine Immune's management team and ensure that shareholders' interests are well served. Alpine Immune's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alpine Immune's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Temre Johnson, Head Communications | ||
| Remy Durand, Chief Officer | ||
| Andrew MD, Chief Officer | ||
| Paul Rickey, CFO, Senior Vice President Secretary | ||
| Stanford MD, President Development | ||
| Wayne Gombotz, Chief Officer | ||
| Mitchell MD, Executive CEO | ||
| Pamela Holland, VP Research | ||
| Wolfgang MD, Chief Officer | ||
| Christina Yi, Chief Officer |
Alpine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alpine Immune a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.1 | |||
| Profit Margin | (0.65) % | |||
| Operating Margin | (3.23) % | |||
| Current Valuation | 4.16 B | |||
| Shares Outstanding | 68.6 M | |||
| Shares Owned By Insiders | 4.60 % | |||
| Shares Owned By Institutions | 99.46 % | |||
| Number Of Shares Shorted | 3.89 M | |||
| Price To Earning | (32.69) X |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in Alpine Stock
If you are still planning to invest in Alpine Immune Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alpine Immune's history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |